No Data
TD Cowen Maintains Takeda Pharmaceutical(TAK.US) With Buy Rating, Announces Target Price $16
Analysts Offer Insights on Healthcare Companies: Lineage Therap (LCTX), Veeva Systems (VEEV) and Takeda Pharmaceutical Company (TAK)
Chordia Research Memo (2): Spin-off from takeda pharmaceuticals sp adr, focusing on the development of anti-cancer drugs.
■Company Overview of Chordia Therapeutics＜190A＞. 1. Company History The company was founded in October 2017 as a biotech venture by six drug discovery researchers who had been developing anti-cancer drugs of low molecular compounds at Takeda Pharmaceuticals. They selected four candidates from the pipeline that had been developed during their time at Takeda Pharmaceuticals and entered into an exclusive global license agreement for research, development, manufacturing, and sales with Takeda Pharmaceuticals in November of the same year.
Global Companies With at Least 50% U.S. Revenue Exposure as Trump Eyes Tariffs: BofA
US Manufacturing Index Rises To 43, Highest Since 2020
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients